
Peer reviewed version
License (if available): CC BY-NC-ND
Link to published version (if available): 10.1016/S1473-3099(20)30021-9

Link to publication record in Explore Bristol Research
PDF-document

This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Elsevier at https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30021-9/fulltext . Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research
General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/
**Abstract:**

Our understanding of congenital infections is based on prospective studies of women infected in pregnancy. The European Union has funded three consortia to study Zika virus (ZIKV), each including a prospective study of pregnant women. Another has been funded by National Institutes of Health. This personal view sets out the study designs required to research ZIKV, and questions whether funding academics in the EU and US to work with collaborators in outbreak areas is an effective strategy. Three years after the 2015-2016 outbreaks, these collaborations have taught us little about ZIKV vertical transmission. In the time taken to approve funding, agree contracts, secure ethics approval, and equip laboratories, Zika had largely disappeared. By contrast, prospective studies based on local surveillance and standard of care (SOC) protocols have already provided valuable data. Threats to fetal and child health pose new challenges for global preparedness requiring support for the design and implementation of locally appropriate protocols. These can answer the key questions earlier and at lower cost. Local protocols can also provide a framework for recruitment of unexposed controls required to study less specific outcomes. Other priorities include accelerated development of non-invasive tests, and longer-term storage of neonatal and antenatal samples to facilitate retrospective reconstruction of cohort studies.
Response to Editors.

Thank you for your email.

Editorial comments: A handful of revisions are required before we can accept this paper. Please include a proper title page. In the abstract you need some aims "In this Personal View, we aimed to do x,y,z", and refer to this piece as a Personal View at the end of your intro.

We have restructured the abstract to add a statement regarding the purpose of the piece, and this now links better to the final sentence of the introduction.

Table 2 should be table 2 and 3, we wouldn’t split a table like this. All abbreviations need to be spelt out in the tables as footnotes.

Table 2 has been converted to Tables 2 and 3, and references to Tables 2,3,4 in the text have been amended.

I need two forms uploading to EES from each author please - ICJME form (with conflicts matching exactly those stated in text) and a signed form, also signed by the corresponding author. Please see our author guidelines and upload two forms per author, labelled as their surname.

Done

I also need a signed statement from Tom Byrne stating that he is happy to appear in the acknowledgements. Please make sure you have conformed to all our author guidelines plus the points below.

Done
Researching Zika in pregnancy: lessons for global preparedness

AE Ades PhD. Department of Population Health Science, University of Bristol Medical School, 38 Whatley Road, Bristol BS8 2PS, United Kingdom

Claire Thorne PhD, Population Policy and Practice Programme, University College London Great Ormond Street Institute of Child Health, 30 Guilford Street, London WC1N 1EH, United Kingdom

Antoni Soriano-Arandes PhD. Pediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Universitari Vall d’Hebron, Vall d’Hebron Research Institute, Barcelona, Spain

Catherine S Peckham MD. Population Policy and Practice Programme, University College London Great Ormond Street Institute of Child Health, 30 Guilford Street, London WC1N 1EH, United Kingdom

David W Brown PhD. Fundação Oswaldo Cruz, Flavivirus Reference Laboratory, Rio de Janeiro, Brazil

Daniel Lang PhD. Fondazione Penta Onlus. Rua Correia de Lemos, 684 #142. São Paulo, SP, Brazil

J Glenn Morris MD. Emerging Pathogens Institute, University of Florida, Gainesville, FL, USA

Celia D C Christie MD. Department of Child and Adolescent Health, University of the West Indies, Mona Campus, Kingston, Jamaica.

Carlo Giaquinto MD. Dipartimento di Salute della Donna e del Bambino, Università degli Studi di Padova, Via Giustiniani, 3 - 35128 Padova. Italy

Corresponding author:

AE Ades PhD. Department of Population Health Science, University of Bristol Medical School, 38 Whatley Road, Bristol BS8 2PS, United Kingdom

t.ades@bristol.ac.uk

(44)-117-928-7338

Zika global prep rev3 November 28 2019
Abstract

Our understanding of congenital infections is based on prospective studies of women infected in pregnancy. The European Union has funded three consortia to study Zika virus (ZIKV), each including a prospective study of pregnant women. Another has been funded by National Institutes of Health. This personal view sets out the study designs required to research ZIKV, and questions whether funding academics in the EU and US to work with collaborators in outbreak areas is an effective strategy. Three years after the 2015-2016 outbreaks, these collaborations have taught us little about ZIKV vertical transmission. In the time taken to approve funding, agree contracts, secure ethics approval, and equip laboratories, Zika had largely disappeared. By contrast, prospective studies based on local surveillance and standard of care (SOC) protocols have already provided valuable data. Threats to fetal and child health pose new challenges for global preparedness requiring support for the design and implementation of locally appropriate protocols. These can answer the key questions earlier and at lower cost. Local protocols can also provide a framework for recruitment of unexposed controls required to study less specific outcomes. Other priorities include accelerated development of non-invasive tests, and longer-term storage of neonatal and antenatal samples to facilitate retrospective reconstruction of cohort studies.

<208 words>

Keywords: Zika Virus, pregnancy, vertical transmission, prospective cohort studies, standard of care
Introduction

Past epidemics have triggered global initiatives to strengthen preparedness against emerging infectious disease threats, focusing on surveillance, detection and outbreak containment.\textsuperscript{1–4} It has been recognized that the higher risks faced by pregnant women and their infants during epidemics have often been overlooked within global preparedness frameworks,\textsuperscript{5,6} but emerging infections with teratogenic effects pose an entirely new set of challenges, particularly around research preparedness.

The Zika virus (ZIKV) epidemic in 2015/2016, following the re-emergence of ZIKV in Asia and the Pacific in 2013\textsuperscript{7}, was unexpected.\textsuperscript{4} During the outbreak in Brazil from 2015\textsuperscript{8,9}, detection of babies with microcephaly and other abnormalities\textsuperscript{10,11} led to the identification of ZIKV as a teratogen, as seen for other congenital infections such as rubella or cytomegalovirus (CMV), but not previously observed for arboviruses. The Pan-American Health Organization issued an Epidemiological Alert in May 2015\textsuperscript{12} and WHO declared a Public Health Emergency of International Concern in February 2016.\textsuperscript{13} The need for a coordinated research response was recognized quickly. The Global Research Collaboration for Infectious Disease Preparedness was engaged (www.glopid-r.org), and the European Commission (EC) issued a call for research and preparedness activities. The three EC consortia (Zika-PLAN (zikaplan.tghn.org/),\textsuperscript{14} ZIKAlliance (zikalliance.tghn.org), and ZIKAction (zikaction.org/)) are multi-disciplinary programmes, each including prospective vertical transmission cohort studies. In the US, the National Institutes for Health launched the ZIP (Zika in Pregnancy) Study (clinicaltrials.gov/ct2/show/NCT02856984). These projects have multiple field sites in the Caribbean, and Central and South America.

Over three years since the Zika alerts were issued several important prospective vertical transmission studies have been published,\textsuperscript{15–18} but none from these externally-funded programmes. ZIKAlliance has pointed to “familiar barriers”, citing delays in the funding process and ethical approvals, and diagnostic challenges.\textsuperscript{19} They have argued for a “permanent … research capacity” with structured funding for a rapid response infrastructure.

In this personal view, we explain why prospective studies to investigate Zika VT require particular design features, and consider other ways in which such studies could be originated and set in motion. Should it be the traditional pattern whereby Western academics are granted funds to work with research collaborators in affected areas, or can prospective studies be built onto appropriately designed and implemented local standard of care (SOC) protocols?
Role of prospective cohort studies in understanding vertical transmission

Understanding of congenital infections, such as rubella, CMV, toxoplasmosis, hepatitis C virus (HCV) and HIV, has been based largely on prospective cohort studies of pregnant women and their children. Pregnancies at risk are identified by screening women for markers of the relevant pathogen, and then followed forward with a more intensive care protocol, the outcome of pregnancy is recorded, and the newborn tested for infection acquired in utero or intrapartum.

The protocol for identifying pregnancies at risk depends on the pathogen. With chronic infections, such as HIV and HCV, IgG antibody testing identifies pregnancies at risk. With toxoplasmosis, the fetus is at risk only following primary infection in pregnancy, with at-risk pregnancies identified by repeat serological testing of susceptible (IgG-negative) women. This protocol would be less effective in detecting pregnancies at risk of congenital CMV, where non-primary infections also pose a risk.

The key property of the prospective cohort design is that it is women who are recruited, as early as possible before delivery, not the babies. Otherwise there is a risk of selectively recruiting pregnancies with adverse outcomes. Ascertainment of infection in pregnancy should therefore pre-date, or at least be independent of, any examination of the fetus (e.g. ultrasound scan) or newborn.

Prospective studies aim to estimate the vertical transmission rate - the probability that the fetus/newborn is infected, given an infected mother. In classic studies of HIV, CMV, toxoplasmosis, the second key parameter is the rate of adverse outcomes in vertically-infected infants (Table 1). With less specific outcomes, uninfected infants of women infected during pregnancy constitute a control group (Control group 1 in Table 1). Infants of unexposed women, who have not been infected in pregnancy, can form a second control group (Table 1); this is not routinely included in many prospective studies, but essential to study outcomes resulting directly from maternal infection, without the infection crossing to the fetus. Examples are prematurity, low birthweight and miscarriage, which have been reported with dengue, malaria and other infections.

The prospective study design as applied to Zika

Applying the prospective design to ZIKV is not straightforward. Firstly, only a few of the components of Congenital Zika Syndrome (CZS) are specific to ZIKV and some require intensive investigation to detect. A control group is therefore essential. Second, PCR+ or IgM+ findings in newborn samples confirm congenital infection, but these markers are absent in a high proportion of CZS cases, despite their relatively high analytic sensitivity. Clearance of virus from amniotic fluid, and
transient viremia in fetal blood, accompanied by post mortem isolation of ZIKV from brain tissue, suggest that the virus can infect the fetus, causing serious damage but then clearing without leaving an immunological trace. As presence or absence of congenital infection cannot be reliably established, a control Group 1 cannot be identified, and unexposed women and their offspring (Control Group 2) are required (Table 1).

Identifying maternal infection in pregnancy (MIP) is also difficult with ZIKV. While MIP can be confirmed by PCR RNA, even the most intense PCR-based screening programme is likely to miss cases of MIP because most ZIKV infections are asymptomatic, and the PCR response may last no more than 7 days. Thus, failure to detect ZIKV RNA does not demonstrate “No MIP”. An IgG negative test in a woman at delivery is suggestive of No MIP, but little is known about ZIKV serology dynamics. In any case, this marker would only be useful in Zika-naïve populations exposed over a short period. Seroconversion is a reliable indicator of MIP if cross-reactions to other flavivirus antibody can be excluded. Tests of recent infection such as IgM, IgG3, or avidity assays have poor specificity, and even if cross-reactions are ruled out, may only reflect an infection that cleared before pregnancy. Probably, the best classification of maternal infection that can be achieved is likely to be along the lines of: confirmed, suspected, and no evidence of MIP (although tested).

**Standard of care protocols for women exposed to Zika in pregnancy**

Recruitment into a formal prospective study requires informed consent to investigations that would not ordinarily be carried out under a SOC protocol. The question for study designers is therefore: what additional investigations are required, and in which patients, that are not already specified for SOC?

Most countries in Latin America and the Caribbean made ZIKV a notifiable disease, creating a de facto surveillance system in which (symptomatic) pregnant women could be referred into a protocol for care in pregnancy. Early protocols in affected countries were therefore restricted to women with symptoms in pregnancy (Table 2). Later, in better-resourced settings, testing was extended to all pregnant women exposed to the outbreak, for example based on repeat serology. The current CDC protocol specifies 3 PCR tests through pregnancy. However, the key issue is whether the SOC provides for testing for congenital infection and follow-up of all newborns delivered to women with a confirmed infection in pregnancy, or only if there are congenital abnormalities (Table 2). Guidance from the Brazilian Ministry of Health has followed the latter course, in common with May 2016 guidelines issued by WHO. The four prospective studies funded through international collaborations (Table 3) offer a similar mix of protocols.
The response of WHO to ZIKV has been confused. Like the earlier CDC guidance,48 WHO recommended testing of women reporting symptoms with additional ultrasound to identify fetal malformations. WHO argued against testing asymptomatic women, even in areas of high ZIKV incidence, as it failed on three of the Wilson & Junger screening criteria:49 poorly understood natural history, lack of effective treatment, and low specificity of diagnostic tests. But it is unclear why these criteria would not also rule out testing symptomatic women. On the other hand, the design of SOC and prospective study protocols alike must be sensitive to the cultural, religious, and medico-legal context: in some countries a confirmed diagnosis of ZIKV in pregnancy may be of little benefit to the mother, and could even lead to harm.50 In such circumstances protocols that go beyond multiple uterine ultrasound may not be feasible.

More critically, the WHO protocol47 made no provision for laboratory testing and follow-up of infants of women with confirmed or suspected ZIKV in pregnancy, unless congenital anomalies were present. Remarkably, positive ZIKV results in pregnancy are described as “false positives” if not resulting in microcephaly. WHO also recommended TORCH testing of neonates born to women with suspected ZIKV in pregnancy, but no tests for congenital ZIKV.51 WHO guidance may have discouraged some Latin American countries from adopting SOCs that would have provided appropriate care to families at risk, and which - as we show below - would concurrently have generated prospective study data on a very large scale.

**Prospective studies based on surveillance and SOC for Zika in pregnancy.**

During a ZIKV outbreak, pregnant women can be referred into a SOC protocol in two ways: either through a ZIKV surveillance system, if they have symptoms; or through repeat serological or virological testing offered by a maternity care provider. Once an SOC is operational, it inevitably generates cohorts of women with confirmed or suspected ZIKV in pregnancy. A “prospective study” is therefore generated simply by carrying out SOC investigations and recording results. All the prospective studies published so far (Table 4) have been generated in this way.

Equally, the same SOC protocols also generate unexposed controls groups (Control Group 2), at least to the extent that this is possible for ZIKV. Thus, some studies have reported outcomes in women who were PCR negative in pregnancy, interpretable as “No evidence of infection in pregnancy” (Table 4). However, detailed imaging, testing and follow-up of apparently healthy newborns born to women without evidence of MIP is explicitly ruled out in CDC guidelines,52 and is likely to require informed consent in any jurisdiction. It is at this point that a formal prospective study can go further than an SOC protocol, by obtaining consent for additional investigations on women and especially...
their newborns. However, the identification of these infants, and ethical approval and logistics for follow-up, will be facilitated if their mothers are already part of a SOC protocol for ZIKV-exposed pregnant women. Follow-up of healthy children with no evidence of MIP raises some specific problems, which we return to below.

Table 4 illustrates that prospective studies based on local SOCs are a viable alternative to collaborative projects funded through US or EC partners (Table 3), even in the absence of funding. In the US, pregnancy outcomes in women potentially ZIKV-exposed and under the CDC protocol are recorded in the US Zika Pregnancy Register (USZPR). This has documented serious brain abnormalities with or without microcephaly in 6% to 15% of pregnancies with confirmed infection, with higher rates following first trimester infection. The authors acknowledge that these are likely to be over-estimates, as USZPR includes pregnancies in which Zika involvement was recognized retrospectively, following detection of anomalies on routine imaging, or at delivery.

Such registers represent a third, and massively under-exploited way of generating prospective data on ZIKV in pregnancy. They can either recruit directly into prospective studies, or be converted into prospective cohort studies retrospectively, by checking the dates of maternal tests relative to delivery, and removing mother-child pairs in which infection in pregnancy was retrospectively ascertained. Just such a retrospective reconstruction of a prospective cohort based on the USZPR was conducted in New York City, reporting markers of congenital infection in 11% and 7% of infants of mothers with “confirmed” and “probable” infection in pregnancy respectively (Table 4).

Other opportunities for retrospective reconstruction of prospective studies

SOC protocols that provide for infant testing and follow-up cannot be established immediately in the context of outbreaks that emerge rapidly and without warning. There will therefore always be a need for retrospective reconstructions. One option is to reconstruct prospective studies from surveillance records of pregnant women who reported symptoms and were tested.

With hindsight, it now seems remarkable that in many countries these pregnancies were not referred to ZIKV-related care protocols in maternity hospitals for additional investigations and infant follow-up. This should remind us that whatever protocols are in place, there may be insufficient resources for laboratory infrastructure and follow-up. However, this process can be carried out retrospectively as a review of maternity and delivery records. Consent could also be sought for clinical follow-up of the infants.
An interesting addition to retrospective review would be to use residual samples routinely collected for newborn sickle cell and/or metabolic screening, as dried blood spots. Many countries in Latin America and the Caribbean have routine newborn screening in national, regional and hospital laboratories.\textsuperscript{59} Newborn dried blood spots have been tested in retrogressively reconstructed cohort studies of congenital infections\textsuperscript{60} but also in irreversibly anonymized studies retaining demographic information.\textsuperscript{61,62} Stored residual newborn dried blood spots could be tested for ZIKV RNA and IgM, retaining information on confirmed or suspected maternal ZIKV infection, and trimester in which symptoms occurred. Laboratory markers cannot be found in a proportion of congenital infection,\textsuperscript{41,42} but studies would set a lower limit on the vertical transmission rate. A sample of newborns of women with no evidence of Zika could also be included, as well as randomly selected controls whose mothers were not notified to surveillance.

A second potential approach to reconstruct prospective studies post-epidemic is the use of stored samples collected during routine antenatal care whilst the outbreak was ongoing. These could be tested for markers of infection; confirmed and suspected cases, plus a sample of those with “No Evidence of MIP”, could again be entered into a record review of pregnancy and neonatal outcomes as above, with the option of obtaining consent for pediatric follow-up, and testing of stored residual newborn screening samples. Joint testing of linked anonymized antenatal and neonatal samples creates many further opportunities for large-scale reconstruction of incidence in pregnant women and vertical transmission, although is logistically more complex.

These designs could be applied now to study the 2015-16 Zika outbreak, but they have a wider significance. There will always be a role for retrospectively reconstructed cohort studies in future outbreaks of pathogens that affect fetal health, especially when no clear diagnostic pathway, or even the pathogen, is identified until later. Such studies may be especially valuable in countries where medical, religious, legal or cultural constraints limit the benefit of a prospective diagnosis of ZIKV in pregnancy. There are logistic requirements: if conducted prospectively, studies based on surveillance reports require only coordination between the surveillance centre, the relevant laboratory and the maternity hospital.\textsuperscript{15,17,18} However, in a retrospective design, these three sets of patient records have to be linked. This can be done using names, addresses, and dates of birth, but record linkage can be greatly facilitated by having unique common identifier, such as the mother’s national security number, on all records, including those of the infant.

Retrospective designs require neonatal and antenatal samples to be stored for longer, which has a cost. Resources could be conserved by focusing on a small number of maternity hospitals serving representative populations, or by initiating sample storage only when an outbreak is detected.
Retrospective studies including “control” mother-child pairs may also require consent, which could perhaps be obtained on a universal basis during an outbreak.

**Role of international agencies and funders in global preparedness**

Only prospective studies can fully answer the key scientific and public health questions around ZIKV infection in pregnancy and its consequences, ideally including an unexposed control group. We have argued that SOC protocols for pregnant women provide a feasible approach, allowing autonomy of local institutional review boards, and ensuring access to the relevant diagnostics and to locally trained research and nursing staff integrated within the health care system. This resolves the delays and barriers that confront prospective studies established by externally-funded researchers (ethics approvals, creation of data collection systems and laboratory infrastructure). Furthermore, externally-originated research protocols may do little to foster global preparedness if the infrastructure is unsupported once the project ends.

One of the difficulties in studying outcomes of ZIKV in pregnancy is testing and follow-up of healthy children, especially when maternal infection is not apparent. It is recognized that global preparedness demands much faster development of diagnostics, but the particular need for non-invasive tests may not have been appreciated. Capillary blood samples collected by heel prick are well accepted, widely used with rapid diagnostic tests (RDTs) and can be dried and stored long-term. Oral fluid samples contain the same antibody pattern as serum and are used for measles and rubella case-based surveillance, for HIV RDTs, and extensively for virus detection by PCR. Throat swabs are used for diagnosis of congenital CMV.

We believe that global preparedness must focus more on the care of pregnant women and their children, with the primary task being the development of culturally sensitive SOC protocols that are appropriate to settings and resources available, backed up by assistance in implementing them, including approaches to data capture, recording and linkage. These SOCs represent de facto prospective studies that will answer the key research questions more rapidly than internationally-led research studies. Furthermore, prospective studies can be reconstructed on a very large scale, with appropriate filtering out of retrospectively-ascertained maternal infection, from registers recording outcomes under SOC. For more subtle outcomes, informed consent would be needed to follow-up unexposed “control” infants, but this can be built onto SOC protocols.

Strengthened surveillance is a key component of preparedness: a focus on pregnancy would prioritize surveillance for stillbirths, neonatal mortality, congenital malformations, auditory and ophthalmological problems. Meanwhile, between epidemics, and before the next new pathogen
emerges with potential for congenital infection, international agencies should devise mechanisms for accelerated development of non-invasive diagnostics, and promote facilities for longer-term storage of routinely collected antenatal and neonatal samples, which can be linked to maternity and pediatric records. No matter how rapid the response to an emerging pathogen, retrospective studies based on stored samples will always be needed.

< 2988 / 3000 words>

Contributors
The paper arose from discussions at the November 2017 ZIKAction consortium meeting at University of Florida, Gainesville, FL. AEA drafted the paper with input from all co-authors. The final decision to submit was taken by CDCC and CT, who co-lead the ZIKAction vertical transmission work package. CG is the ZIKAction principal investigator. All co-authors read, contributed to and approved the final version.

Declaration of interests
CT received funding from Penta Foundation and Abb Vie during the period of the study, outside the submitted work. All authors are members of the ZikAction consortium

Acknowledgements
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 734857. The sponsors had no role in the origination or writing of the report. We thank Tom Byrne for assistance in preparing the manuscript for publication.
**TABLES**

**Table 1.** Design of a prospective vertical transmission study. The table shows cell frequency counts $a, b...f$ of birth outcomes broken down by congenital infection status, presence or absence of adverse outcomes, and maternal infection status. The Vertical Transmission rate is estimated by $(a+b)/(a+b+c+d)$. The rate of adverse outcomes conditional on congenital infection is $a/(a+b)$. For less specific adverse outcomes this can be compared with the rate of outcomes in newborns with no congenital infection, $c/(c+d)$, whose mothers were infected in pregnancy (Control Group 1). An overall adverse event rate can be estimated, $(a+c)/(a+b+c+d)$, pooling congenital infection and No congenital infection. Follow-up of births where there has been no maternal infection in pregnancy (MIP) represent a second control group (Control Group 2), with a rate of adverse outcomes, $e/(e+f)$. In the absence of clear diagnostic criteria for congenital infection, as with ZIKV, this second control group is needed.

Some cells have zeros as there can be no congenital infection without maternal infection in pregnancy.

<table>
<thead>
<tr>
<th>Congenital Infection (CI) Status</th>
<th>Maternal Infection in Pregnancy (MIP) Status</th>
<th>MIP</th>
<th>No MIP</th>
</tr>
</thead>
<tbody>
<tr>
<td>CI</td>
<td>Adverse outcomes</td>
<td>$a$</td>
<td>$0$</td>
</tr>
<tr>
<td>No Adverse outcomes</td>
<td></td>
<td>$b$</td>
<td>$0$</td>
</tr>
<tr>
<td>No CI</td>
<td>Adverse outcomes</td>
<td>$c$</td>
<td>$E$</td>
</tr>
<tr>
<td>No Adverse outcomes</td>
<td></td>
<td>$d$</td>
<td>$F$</td>
</tr>
<tr>
<td>State</td>
<td>Date</td>
<td>Provision for screening women potentially exposed during pregnancy</td>
<td>Care of newborn mother with confirmed ZIKV in pregnancy</td>
</tr>
<tr>
<td>-------</td>
<td>------</td>
<td>---------------------------------------------------------------</td>
<td>------------------------------------------------------</td>
</tr>
<tr>
<td>USA</td>
<td>January 2016&lt;sup&gt;48&lt;/sup&gt;</td>
<td>PCR, IgM if symptomatic, additional U/S if asymptomatic</td>
<td>Laboratory testing for congenital ZIKV, clinical follow-up</td>
</tr>
<tr>
<td>Brazil</td>
<td>January 2016&lt;sup&gt;68&lt;/sup&gt;</td>
<td>Testing and U/S in symptomatic</td>
<td>Follow-up if microcephaly</td>
</tr>
<tr>
<td>France</td>
<td>January 2016&lt;sup&gt;69&lt;/sup&gt;</td>
<td>PCR, IgM additional U/S if symptomatic</td>
<td>Laboratory testing for congenital ZIKV, clinical follow-up</td>
</tr>
<tr>
<td>France</td>
<td>April 2016&lt;sup&gt;70&lt;/sup&gt;</td>
<td>PCR, IgM testing regardless of symptoms</td>
<td>Laboratory testing, clinical follow-up</td>
</tr>
<tr>
<td>WHO</td>
<td>May 2016&lt;sup&gt;47&lt;/sup&gt;</td>
<td>Testing and U/S if symptomatic</td>
<td>Follow-up if microcephaly</td>
</tr>
<tr>
<td>WHO</td>
<td>August 2016&lt;sup&gt;51&lt;/sup&gt;</td>
<td>Not applicable</td>
<td>TORCH screen, but no tests for Congenital ZIKV</td>
</tr>
<tr>
<td>Brazil</td>
<td>November 2016&lt;sup&gt;71&lt;/sup&gt;</td>
<td>Testing and U/S if symptomatic</td>
<td>Follow-up if symptoms of ZIKV in first 3 years</td>
</tr>
<tr>
<td>USA</td>
<td>July 2017&lt;sup&gt;72&lt;/sup&gt;</td>
<td>3 PCR tests, additional U/S, regardless of symptoms</td>
<td>Laboratory testing for congenital ZIKV, clinical follow-up</td>
</tr>
<tr>
<td>Spain</td>
<td>April 2017&lt;sup&gt;73&lt;/sup&gt;</td>
<td>PCR, IgM and IgG regardless of symptoms, alongside U/S; if IgG(+) then PRNT-ZIKV</td>
<td>Laboratory testing for congenital ZIKV and clinical follow-up for all born to ZIKV-infected mothers (probable and confirmed)</td>
</tr>
</tbody>
</table>
Table 3. Protocols of four international collaborative prospective studies, funded through US or EU partners

<table>
<thead>
<tr>
<th>Study</th>
<th>Funder</th>
<th>Provision for screening women potentially exposed during pregnancy</th>
<th>Care of newborn of mother with confirmed ZIKV in pregnancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>ZIKAlliance</td>
<td>European Commission</td>
<td>Repeat serological and PCR tests</td>
<td>Laboratory testing for congenital ZIKV, clinical follow-up</td>
</tr>
<tr>
<td>ZIKAction</td>
<td>European Commission</td>
<td>Repeat serological tests</td>
<td>Laboratory testing for congenital ZIKV, clinical follow-up</td>
</tr>
<tr>
<td>ZikaPLAN</td>
<td>European Commission</td>
<td>ZIKV Symptoms in pregnancy</td>
<td>Clinical follow-up from week 6.</td>
</tr>
<tr>
<td>Zika In Pregnancy (ZIP)</td>
<td>National Institutes of Health</td>
<td>Repeat PCR tests</td>
<td>Laboratory testing for congenital ZIKV, clinical follow-up</td>
</tr>
</tbody>
</table>
Table 4. Prospective studies published before April 2019: method of recruitment, cohorts followed, prevalence of adverse outcomes and of markers of congenital infection (CI).

<table>
<thead>
<tr>
<th>Region</th>
<th>Recruitment</th>
<th>Cohorts reported</th>
<th>Adverse Outcomes, %</th>
<th>Markers of CI, %</th>
</tr>
</thead>
</table>
| Brazil                  | Rash in pregnancy, dengue surveillance programme | 1. Confirmed MIP (n=134)  
2. No Evidence of MIP (n=73) | 46% “Adverse outcomes”  
11.5% | NR |
| Texas, USA              | Prospective USZPR                                 | 1. Confirmed or probable MIP (n=28)  
2. No Evidence of MIP (n=306) | 4% CZS  
NR | 7%  
NR |
| French Guiana           | Three PCR tests on all pregnant women            | 1. Confirmed MIP (n=301)  
2. No Evidence of MIP (n=399) | 9% “CNS involvement”  
4% | NR  
NR |
| French Guiana           | Three PCR tests on all pregnant women            | 1. Confirmed MIP (n=291) | 4% “Severe complications”  
35% | |
| Martinique & Guadeloupe | ZIKV Surveillance, symptomatic women             | 1. Confirmed MIP (n=555) | 10% “Neurological and ocular defects” | NR |
| Colombia                | National surveillance                            | 1. ZIKV Symptoms in pregnancy, 3rd trimester (n=c.570) | 0% “microcephaly <3SD or brain abnormalities” | NR |
| New York City, USA      | Retrospective reconstruction USZPR,              | 1. Confirmed (n=80)  
2. Suspected (n=207) | NR  
NR | 11%  
7% |
| Brazil                  | Symptoms of ZIKV in pregnancy                    | 1. Confirmed MIP (n=57) | 28% “Adverse outcomes”  
26% | |
| Barcelona               | ZIKV surveillance travellers                     | 1. Confirmed MIP (n=9)  
2. Probable MIP (n=62) | 33% “Adverse outcomes”  
0% | NR  
NR |

NR: Not Reported; MIP: Maternal Infection in Pregnancy; USZPR United States Zika in Pregnancy Register
References


Researching Zika in pregnancy: lessons for global preparedness

AE Ades PhD. Department of Population Health Science, University of Bristol Medical School, 38 Whatley Road, Bristol BS8 2PS, United Kingdom

Claire Thorne PhD, Population Policy and Practice Programme, University College London Great Ormond Street Institute of Child Health, 30 Guilford Street, London WC1N 1EH, United Kingdom

Antoni Soriano-Arandes PhD. Pediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Universitari Vall d’Hebron, Vall d’Hebron Research Institute, Barcelona, Spain

Catherine S Peckham MD. Population Policy and Practice Programme, University College London Great Ormond Street Institute of Child Health, 30 Guilford Street, London WC1N 1EH, United Kingdom

David W Brown PhD. Fundacão Oswaldo Cruz, Flavivirus Reference Laboratory, Rio de Janeiro, Brazil

Daniel Lang PhD. Fondazione Penta Onlus. Rua Correia de Lemos, 684 #142. São Paulo, SP, Brazil

J Glenn Morris MD. Emerging Pathogens Institute, University of Florida, Gainesville, FL, USA

Celia D C Christie MD. Department of Child and Adolescent Health, University of the West Indies, Mona Campus, Kingston, Jamaica.

Carlo Giaquinto MD. Dipartimento di Salute della Donna e del Bambino, Università degli Studi di Padova, Via Giustiniani, 3 - 35128 Padova. Italy

**Corresponding author:**

AE Ades PhD. Department of Population Health Science, University of Bristol Medical School, 38 Whatley Road, Bristol BS8 2PS, United Kingdom

t.ades@bristol.ac.uk

**(44)-117-928-7338**

Zika global prep rev3  November 28 2019
Abstract

Our understanding of congenital infections is based on prospective studies of women infected in pregnancy. The European Union has funded three consortia to study Zika virus (ZIKV), each including a prospective study of pregnant women. Another has been funded by National Institutes of Health. This personal view sets out the study designs required to research ZIKV, and questions whether funding academics in the EU and US to work with collaborators in outbreak areas is an effective strategy. Three years after the 2015-2016 outbreaks, these collaborations have taught us little about ZIKV vertical transmission. In the time taken to approve funding, agree contracts, secure ethics approval, and equip laboratories, Zika had largely disappeared. By contrast, prospective studies based on local surveillance and standard of care (SOC) protocols have already provided valuable data. Threats to fetal and child health pose new challenges for global preparedness requiring support for the design and implementation of locally appropriate protocols. These can answer the key questions earlier and at lower cost. Local protocols can also provide a framework for recruitment of unexposed controls required to study less specific outcomes. Other priorities include accelerated development of non-invasive tests, and longer-term storage of neonatal and antenatal samples to facilitate retrospective reconstruction of cohort studies.

<208 words>

Keywords: Zika Virus, pregnancy, vertical transmission, prospective cohort studies, standard of care
Introduction

Past epidemics have triggered global initiatives to strengthen preparedness against emerging infectious disease threats, focusing on surveillance, detection and outbreak containment.1–4 It has been recognized that the higher risks faced by pregnant women and their infants during epidemics have often been overlooked within global preparedness frameworks,5,6 but emerging infections with teratogenic effects pose an entirely new set of challenges, particularly around research preparedness.

The Zika virus (ZIKV) epidemic in 2015/2016, following the re-emergence of ZIKV in Asia and the Pacific in 20137, was unexpected.4 During the outbreak in Brazil from 20158,9, detection of babies with microcephaly and other abnormalities10,11 led to the identification of ZIKV as a teratogen, as seen for other congenital infections such as rubella or cytomegalovirus (CMV), but not previously observed for arboviruses. The Pan-American Health Organization issued an Epidemiological Alert in May 201512 and WHO declared a Public Health Emergency of International Concern in February 2016.13 The need for a coordinated research response was recognized quickly. The Global Research Collaboration for Infectious Disease Preparedness was engaged (www.glopid-r.org), and the European Commission (EC) issued a call for research and preparedness activities. The three EC consortia (Zika-PLAN (zikaplan.tghn.org/),14 ZIKAlliance (zikalliance.tghn.org), and ZIKAction (zikaction.org/)) are multi-disciplinary programmes, each including prospective vertical transmission cohort studies. In the US, the National Institutes for Health launched the ZIP (Zika in Pregnancy) Study (clinicaltrials.gov/ct2/show/NCT02856984). These projects have multiple field sites in the Caribbean, and Central and South America.

Over three years since the Zika alerts were issued several important prospective vertical transmission studies have been published,15–18 but none from these externally-funded programmes. ZIKAlliance has pointed to “familiar barriers”, citing delays in the funding process and ethical approvals, and diagnostic challenges.19 They have argued for a “permanent … research capacity” with structured funding for a rapid response infrastructure.

In this personal view, we explain why prospective studies to investigate Zika VT require particular design features, and consider other ways in which such studies could be originated and set in motion. Should it be the traditional pattern whereby Western academics are granted funds to work with research collaborators in affected areas, or can prospective studies be built onto appropriately designed and implemented local standard of care (SOC) protocols?
Role of prospective cohort studies in understanding vertical transmission

Understanding of congenital infections, such as rubella, CMV, toxoplasmosis, hepatitis C virus (HCV) and HIV, has been based largely on prospective cohort studies of pregnant women and their children.20–24 Pregnancies at risk are identified by screening women for markers of the relevant pathogen, and then followed forward with a more intensive care protocol, the outcome of pregnancy is recorded, and the newborn tested for infection acquired in utero or intrapartum.

The protocol for identifying pregnancies at risk depends on the pathogen. With chronic infections, such as HIV and HCV, IgG antibody testing identifies pregnancies at risk.24,25 With toxoplasmosis the fetus is at risk only following primary infection in pregnancy, with at-risk pregnancies identified by repeat serological testing of susceptible (IgG-negative) women. This protocol would be less effective in detecting pregnancies at risk of congenital CMV, where non-primary infections also pose a risk.26

The key property of the prospective cohort design is that it is women who are recruited, as early as possible before delivery, not the babies. Otherwise there is a risk of selectively recruiting pregnancies with adverse outcomes. Ascertainment of infection in pregnancy should therefore pre-date, or at least be independent of, any examination of the fetus (e.g. ultrasound scan) or newborn.

Prospective studies aim to estimate the vertical transmission rate - the probability that the fetus/newborn is infected, given an infected mother. In classic studies of HIV,27,28 CMV29 and toxoplasmosis,22,30,31 the second key parameter is the rate of adverse outcomes in vertically-infected infants (Table 1). With less specific outcomes, uninfected infants of women infected during pregnancy constitute a control group (Control group 1 in Table 1).32,33 Infants of unexposed women, who have not been infected in pregnancy, can form a second control group (Table 1)34; this is not routinely included in many prospective studies, but essential to study outcomes resulting directly from maternal infection, without the infection crossing to the fetus. Examples are prematurity, low birthweight and miscarriage, which have been reported with dengue,35 malaria36 and other infections.37

The prospective study design as applied to Zika

Applying the prospective design to ZIKV is not straightforward. Firstly, only a few of the components of Congenital Zika Syndrome (CZS) are specific to ZIKV and some require intensive investigation to detect.38 A control group is therefore essential. Second, PCR+ or IgM+ findings in newborn samples confirm congenital infection, but these markers are absent in a high proportion of CZS cases,39,40 despite their relatively high analytic sensitivity. Clearance of virus from amniotic fluid,16,41 and
transient viremia in fetal blood, accompanied by post mortem isolation of ZIKV from brain tissue, suggest that the virus can infect the fetus, causing serious damage but then clearing without leaving an immunological trace. As presence or absence of congenital infection cannot be reliably established, a control Group 1 cannot be identified, and unexposed women and their offspring (Control Group 2) are required (Table 1).

Identifying maternal infection in pregnancy (MIP) is also difficult with ZIKV. While MIP can be confirmed by PCR RNA, even the most intense PCR-based screening programme is likely to miss cases of MIP because most ZIKV infections are asymptomatic, and the PCR response may last no more than 7 days. Thus, failure to detect ZIKV RNA does not demonstrate “No MIP”. An IgG negative test in a woman at delivery is suggestive of No MIP, but little is known about ZIKV serology dynamics. In any case, this marker would only be useful in Zika-naïve populations exposed over a short period. Seroconversion is a reliable indicator of MIP if cross-reactions to other flavivirus antibody can be excluded. Tests of recent infection such as IgM, IgG3, or avidity assays have poor specificity, and even if cross-reactions are ruled out, may only reflect an infection that cleared before pregnancy. Probably, the best classification of maternal infection that can be achieved is likely to be along the lines of: confirmed, suspected, and no evidence of MIP (although tested).

**Standard of care protocols for women exposed to Zika in pregnancy**

Recruitment into a formal prospective study requires informed consent to investigations that would not ordinarily be carried out under a SOC protocol. The question for study designers is therefore: what additional investigations are required, and in which patients, that are not already specified for SOC?

Most countries in Latin America and the Caribbean made ZIKV a notifiable disease, creating a de facto surveillance system in which (symptomatic) pregnant women could be referred into a protocol for care in pregnancy. Early protocols in affected countries were therefore restricted to women with symptoms in pregnancy (Table 2). Later, in better-resourced settings, testing was extended to all pregnant women exposed to the outbreak, for example based on repeat serology. The current CDC protocol specifies 3 PCR tests through pregnancy. However, the key issue is whether the SOC provides for testing for congenital infection and follow-up of all newborns delivered to women with a confirmed infection in pregnancy, or only if there are congenital abnormalities (Table 2). Guidance from the Brazilian Ministry of Health has followed the latter course, in common with May 2016 guidelines issued by WHO. The four prospective studies funded through international collaborations (Table 3) offer a similar mix of protocols.
The response of WHO to ZIKV has been confused. Like the earlier CDC guidance, WHO recommended testing of women reporting symptoms with additional ultrasound to identify fetal malformations. WHO argued against testing asymptomatic women, even in areas of high ZIKV incidence, as it failed on three of the Wilson & Junger screening criteria: poorly understood natural history, lack of effective treatment, and low specificity of diagnostic tests. But it is unclear why these criteria would not also rule out testing symptomatic women. On the other hand, the design of SOC and prospective study protocols alike must be sensitive to the cultural, religious, and medico-legal context: in some countries a confirmed diagnosis of ZIKV in pregnancy may be of little benefit to the mother, and could even lead to harm. In such circumstances protocols that go beyond multiple uterine ultrasound may not be feasible.

More critically, the WHO protocol made no provision for laboratory testing and follow-up of infants of women with confirmed or suspected ZIKV in pregnancy, unless congenital anomalies were present. Remarkably, positive ZIKV results in pregnancy are described as “false positives” if not resulting in microcephaly. WHO also recommended TORCH testing of neonates born to women with suspected ZIKV in pregnancy, but no tests for congenital ZIKV. WHO guidance may have discouraged some Latin American countries from adopting SOCs that would have provided appropriate care to families at risk, and which - as we show below - would concurrently have generated prospective study data on a very large scale.

**Prospective studies based on surveillance and SOC for Zika in pregnancy.**

During a ZIKV outbreak, pregnant women can be referred into a SOC protocol in two ways: either through a ZIKV surveillance system, if they have symptoms; or through repeat serological or virological testing offered by a maternity care provider. Once an SOC is operational, it inevitably generates cohorts of women with confirmed or suspected ZIKV in pregnancy. A “prospective study” is therefore generated simply by carrying out SOC investigations and recording results. All the prospective studies published so far have been generated in this way.

Equally, the same SOC protocols also generate unexposed controls groups (Control Group 2), at least to the extent that this is possible for ZIKV. Thus, some studies have reported outcomes in women who were PCR negative in pregnancy, interpretable as “No evidence of infection in pregnancy” (Table 4). However, detailed imaging, testing and follow-up of apparently healthy newborns born to women without evidence of MIP is explicitly ruled out in CDC guidelines, and is likely to require informed consent in any jurisdiction. It is at this point that a formal prospective study can go further than an SOC protocol, by obtaining consent for additional investigations on women and especially...
their newborns. However, the identification of these infants, and ethical approval and logistics for follow-up, will be facilitated if their mothers are already part of a SOC protocol for ZIKV-exposed pregnant women. Follow-up of healthy children with no evidence of MIP raises some specific problems, which we return to below.

Table 4 illustrates that prospective studies based on local SOCs are a viable alternative to collaborative projects funded through US or EC partners (Table 3), even in the absence of funding. In the US, pregnancy outcomes in women potentially ZIKV-exposed and under the CDC protocol are recorded in the US Zika Pregnancy Register (USZPR). This has documented serious brain abnormalities with or without microcephaly in 6% to 15% of pregnancies with confirmed infection, with higher rates following first trimester infection. The authors acknowledge that these are likely to be over-estimates, as USZPR includes pregnancies in which Zika involvement was recognized retrospectively, following detection of anomalies on routine imaging, or at delivery.

Such registers represent a third, and massively under-exploited way of generating prospective data on ZIKV in pregnancy. They can either recruit directly into prospective studies, or be converted into prospective cohort studies retrospectively, by checking the dates of maternal tests relative to delivery, and removing mother-child pairs in which infection in pregnancy was retrospectively ascertained. Just such a retrospective reconstruction of a prospective cohort based on the USZPR was conducted in New York City, reporting markers of congenital infection in 11% and 7% of infants of mothers with “confirmed” and “probable” infection in pregnancy respectively (Table 4).

Other opportunities for retrospective reconstruction of prospective studies

SOC protocols that provide for infant testing and follow-up cannot be established immediately in the context of outbreaks that emerge rapidly and without warning. There will therefore always be a need for retrospective reconstructions. One option is to reconstruct prospective studies from surveillance records of pregnant women who reported symptoms and were tested.

With hindsight, it now seems remarkable that in many countries these pregnancies were not referred to ZIKV-related care protocols in maternity hospitals for additional investigations and infant follow-up. This should remind us that whatever protocols are in place, there may be insufficient resources for laboratory infrastructure and follow-up. However, this process can be carried out retrospectively as a review of maternity and delivery records. Consent could also be sought for clinical follow-up of the infants.
An interesting addition to retrospective review would be to use residual samples routinely collected for newborn sickle cell and/or metabolic screening, as dried blood spots. Many countries in Latin America and the Caribbean have routine newborn screening in national, regional and hospital laboratories.\textsuperscript{59} Newborn dried blood spots have been tested in retrospectively reconstructed cohort studies of congenital infections\textsuperscript{60} but also in irreversibly anonymized studies retaining demographic information.\textsuperscript{61,62} Stored residual newborn dried blood spots could be tested for ZIKV RNA and IgM, retaining information on confirmed or suspected maternal ZIKV infection, and trimester in which symptoms occurred. Laboratory markers cannot be found in a proportion of congenital infection,\textsuperscript{41,42} but studies would set a lower limit on the vertical transmission rate. A sample of newborns of women with no evidence of Zika could also be included, as well as randomly selected controls whose mothers were not notified to surveillance.

A second potential approach to reconstruct prospective studies post-epidemic is the use of stored samples collected during routine antenatal care whilst the outbreak was ongoing. These could be tested for markers of infection; confirmed and suspected cases, plus a sample of those with “No Evidence of MIP”, could again be entered into a record review of pregnancy and neonatal outcomes as above, with the option of obtaining consent for pediatric follow-up, and testing of stored residual newborn screening samples. Joint testing of linked anonymized antenatal and neonatal samples creates many further opportunities for large-scale reconstruction of incidence in pregnant women and vertical transmission, although is logistically more complex.

These designs could be applied now to study the 2015-16 Zika outbreak, but they have a wider significance. There will always be a role for retrospectively reconstructed cohort studies in future outbreaks of pathogens that affect fetal health, especially when no clear diagnostic pathway, or even the pathogen, is identified until later. Such studies may be especially valuable in countries where medical, religious, legal or cultural constraints limit the benefit of a prospective diagnosis of ZIKV in pregnancy. There are logistic requirements: if conducted prospectively, studies based on surveillance reports require only coordination between the surveillance centre, the relevant laboratory and the maternity hospital.\textsuperscript{15,17,18} However, in a retrospective design, these three sets of patient records have to be linked. This can be done using names, addresses, and dates of birth, but record linkage can be greatly facilitated by having unique common identifier, such as the mother’s national security number, on all records, including those of the infant.

Retrospective designs require neonatal and antenatal samples to be stored for longer, which has a cost. Resources could be conserved by focusing on a small number of maternity hospitals serving representative populations, or by initiating sample storage only when an outbreak is detected.
Retrospective studies including “control” mother-child pairs may also require consent, which could perhaps be obtained on a universal basis during an outbreak.

**Role of international agencies and funders in global preparedness**

Only prospective studies can fully answer the key scientific and public health questions around ZIKV infection in pregnancy and its consequences, ideally including an unexposed control group. We have argued that SOC protocols for pregnant women provide a feasible approach, allowing autonomy of local institutional review boards, and ensuring access to the relevant diagnostics and to locally trained research and nursing staff integrated within the health care system. This resolves the delays and barriers that confront prospective studies established by externally-funded researchers (ethics approvals, creation of data collection systems and laboratory infrastructure). Furthermore, externally-originated research protocols may do little to foster global preparedness if the infrastructure is unsupported once the project ends.

One of the difficulties in studying outcomes of ZIKV in pregnancy is testing and follow-up of healthy children, especially when maternal infection is not apparent. It is recognized that global preparedness demands much faster development of diagnostics, but the particular need for non-invasive tests may not have been appreciated. Capillary blood samples collected by heel prick are well accepted, widely used with rapid diagnostic tests (RDTs) and can be dried and stored long-term. Oral fluid samples contain the same antibody pattern as serum and are used for measles and rubella case-based surveillance, for HIV RDTs, and extensively for virus detection by PCR. Throat swabs are used for diagnosis of congenital CMV.

We believe that global preparedness must focus more on the care of pregnant women and their children, with the primary task being the development of culturally sensitive SOC protocols that are appropriate to settings and resources available, backed up by assistance in implementing them, including approaches to data capture, recording and linkage. These SOCs represent de facto prospective studies that will answer the key research questions more rapidly than internationally-led research studies. Furthermore, prospective studies can be reconstructed on a very large scale, with appropriate filtering out of retrospectively-ascertained maternal infection, from registers recording outcomes under SOC. For more subtle outcomes, informed consent would be needed to follow-up unexposed “control” infants, but this can be built onto SOC protocols.

Strengthened surveillance is a key component of preparedness: a focus on pregnancy would prioritize surveillance for stillbirths, neonatal mortality, congenital malformations, auditory and ophthalmological problems. Meanwhile, between epidemics, and before the next new pathogen
emerges with potential for congenital infection, international agencies should devise mechanisms for accelerated development of non-invasive diagnostics, and promote facilities for longer-term storage of routinely collected antenatal and neonatal samples, which can be linked to maternity and pediatric records. No matter how rapid the response to an emerging pathogen, retrospective studies based on stored samples will always be needed.

< 2988 / 3000 words>

Contributors
The paper arose from discussions at the November 2017 ZIKAction consortium meeting at University of Florida, Gainesville, FL. AEA drafted the paper with input from all co-authors. The final decision to submit was taken by CDCC and CT, who co-lead the ZIKAction vertical transmission work package. CG is the ZIKAction principal investigator. All co-authors read, contributed to and approved the final version.

Declaration of interests
CT received funding from Penta Foundation and Abb Vie during the period of the study, outside the submitted work. All authors are members of the ZikAction consortium

Acknowledgements
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 734857. The sponsors had no role in the origination or writing of the report. We thank Tom Byrne for assistance in preparing the manuscript for publication.
**TABLE 1.** Design of a prospective vertical transmission study. The table shows cell frequency counts \(a,b,...f\) of birth outcomes broken down by congenital infection status, presence or absence of adverse outcomes, and maternal infection status. The Vertical Transmission rate is estimated by \(\frac{(a+b)}{(a+b+c+d)}\). The rate of adverse outcomes conditional on congenital infection is \(\frac{a}{(a+b)}\). For less specific adverse outcomes this can be compared with the rate of outcomes in newborns with no congenital infection, \(\frac{c}{(c+d)}\), whose mothers were infected in pregnancy (Control Group 1). An overall adverse event rate can be estimated, \(\frac{(a+c)}{(a+b+c+d)}\), pooling congenital infection and No congenital infection. Follow-up of births where there has been no maternal infection in pregnancy (MIP) represent a second control group (Control Group 2), with a rate of adverse outcomes, \(\frac{e}{(e+f)}\). In the absence of clear diagnostic criteria for congenital infection, as with ZIKV, this second control group is needed.

Some cells have zeros as there can be no congenital infection without maternal infection in pregnancy.

<table>
<thead>
<tr>
<th>Maternal Infection in Pregnancy (MIP) Status</th>
<th>MIP</th>
<th>No MIP</th>
</tr>
</thead>
<tbody>
<tr>
<td>MIP</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cl  Adverse outcomes</td>
<td>(a)</td>
<td>0</td>
</tr>
<tr>
<td>Cl  No Adverse outcomes</td>
<td>(b)</td>
<td>0</td>
</tr>
<tr>
<td>No Cl Adverse outcomes</td>
<td>(c)</td>
<td>(E)</td>
</tr>
<tr>
<td>No Cl No Adverse outcomes</td>
<td>(d)</td>
<td>(F)</td>
</tr>
</tbody>
</table>

### TABLE 1

<table>
<thead>
<tr>
<th>Congenital Infection (CI) Status</th>
<th>Maternal Infection in Pregnancy (MIP) Status</th>
<th>MIP</th>
<th>No MIP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cl Adverse outcomes</td>
<td>(a)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cl No Adverse outcomes</td>
<td>(b)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No Cl Adverse outcomes</td>
<td>(c)</td>
<td></td>
<td>(E)</td>
</tr>
<tr>
<td>No Cl No Adverse outcomes</td>
<td>(d)</td>
<td></td>
<td>(F)</td>
</tr>
</tbody>
</table>

11
Table 2. Standard protocols of care for women exposed to Zika outbreaks

<table>
<thead>
<tr>
<th>State</th>
<th>Date</th>
<th>Provision for screening women potentially exposed during pregnancy</th>
<th>Care of newborn mother with confirmed ZIKV in pregnancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>USA</td>
<td>January 2016</td>
<td>PCR, IgM if symptomatic, additional U/S if asymptomatic</td>
<td>Laboratory testing for congenital ZIKV, clinical follow-up</td>
</tr>
<tr>
<td>Brazil</td>
<td>January 2016</td>
<td>Testing and U/S in symptomatic</td>
<td>Follow-up if microcephaly</td>
</tr>
<tr>
<td>France</td>
<td>January 2016</td>
<td>PCR, IgM additional U/S if symptomatic</td>
<td>Laboratory testing for congenital ZIKV, clinical follow-up</td>
</tr>
<tr>
<td>France</td>
<td>April 2016</td>
<td>PCR, IgM testing regardless of symptoms</td>
<td>Laboratory testing, clinical follow-up</td>
</tr>
<tr>
<td>WHO</td>
<td>May 2016</td>
<td>Testing and U/S if symptomatic</td>
<td>Follow-up if microcephaly</td>
</tr>
<tr>
<td>WHO</td>
<td>August 2016</td>
<td>Not applicable</td>
<td>TORCH screen, but no tests for Congenital ZIKV</td>
</tr>
<tr>
<td>Brazil</td>
<td>November 2016</td>
<td>Testing and U/S if symptomatic</td>
<td>Follow-up if symptoms of ZIKA in first 3 years</td>
</tr>
<tr>
<td>USA</td>
<td>July 2017</td>
<td>3 PCR tests, additional U/S, regardless of symptoms</td>
<td>Laboratory testing for congenital ZIKV, clinical follow-up</td>
</tr>
<tr>
<td>Spain</td>
<td>April 2017</td>
<td>PCR, IgM and IgG regardless of symptoms, alongside U/S; if IgG(+) then PRNT-ZIKV</td>
<td>Laboratory testing for congenital ZIKV and clinical follow-up for all born to ZIKV-infected mothers (probable and confirmed)</td>
</tr>
</tbody>
</table>

U/S Ultrasound; PCR Polymerase Chain Reaction; ZIKV Zika virus
**Table 3. Protocols of four international collaborative prospective studies, funded through US or EU partners**

<table>
<thead>
<tr>
<th>Study</th>
<th>Funder</th>
<th>Provision for screening women potentially exposed during pregnancy</th>
<th>Care of newborn of mother with confirmed ZIKV in pregnancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>ZIKAlliance</td>
<td>European Commission</td>
<td>Repeat serological and PCR tests</td>
<td>Laboratory testing for congenital ZIKV, clinical follow-up</td>
</tr>
<tr>
<td>ZIKAction</td>
<td>European Commission</td>
<td>Repeat serological tests</td>
<td>Laboratory testing for congenital ZIKV, clinical follow-up</td>
</tr>
<tr>
<td>ZikaPLAN</td>
<td>European Commission</td>
<td>ZIKV Symptoms in pregnancy</td>
<td>Clinical follow-up from week 6.</td>
</tr>
<tr>
<td>Zika In Pregnancy (ZIP)</td>
<td>National Institutes of Health</td>
<td>Repeat PCR tests</td>
<td>Laboratory testing for congenital ZIKV, clinical follow-up</td>
</tr>
</tbody>
</table>

PCR Polymerase Chain Reaction; ZIKV Zika virus
Table 4. Prospective studies published before April 2019: method of recruitment, cohorts followed, prevalence of adverse outcomes and of markers of congenital infection (CI).

<table>
<thead>
<tr>
<th>Region</th>
<th>Recruitment</th>
<th>Cohorts reported</th>
<th>Adverse Outcomes, %</th>
<th>Markers of CI, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brazil&lt;sup&gt;18&lt;/sup&gt;</td>
<td>Rash in pregnancy, dengue surveillance programme</td>
<td>1. Confirmed MIP (n=134) 2. No Evidence of MIP (n=73)</td>
<td>46% “Adverse outcomes” 11.5%</td>
<td>NR NR</td>
</tr>
<tr>
<td>Texas, USA&lt;sup&gt;56&lt;/sup&gt;</td>
<td>Prospective USZPR</td>
<td>1. Confirmed or probable MIP (n=28) 2. No Evidence of MIP (n=306)</td>
<td>4% CZS NR</td>
<td>7% NR</td>
</tr>
<tr>
<td>French Guiana&lt;sup&gt;46&lt;/sup&gt;</td>
<td>Three PCR tests on all pregnant women</td>
<td>1. Confirmed MIP (n=301) 2. No Evidence of MIP (n=399)</td>
<td>9% “CNS involvement” 4%</td>
<td>NR NR</td>
</tr>
<tr>
<td>French Guiana&lt;sup&gt;74&lt;/sup&gt;</td>
<td>Three PCR tests on all pregnant women</td>
<td>1. Confirmed MIP (n=291)</td>
<td>4% “Severe complications” 35%</td>
<td></td>
</tr>
<tr>
<td>Martinique &amp; Guadeloupe&lt;sup&gt;15&lt;/sup&gt;</td>
<td>ZIKV Surveillance, symptomatic women</td>
<td>1. Confirmed MIP (n=555)</td>
<td>10% “Neurological and ocular defects” NR</td>
<td></td>
</tr>
<tr>
<td>Colombia&lt;sup&gt;75&lt;/sup&gt;</td>
<td>National surveillance</td>
<td>1. ZIKV Symptoms in pregnancy, 3&lt;sup&gt;rd&lt;/sup&gt; trimester (n=570)</td>
<td>0% “microcephaly &lt;3SD or brain abnormalities” NR</td>
<td></td>
</tr>
<tr>
<td>New York City, USA&lt;sup&gt;58&lt;/sup&gt;</td>
<td>Retrospective reconstruction USZPR, Symptoms of ZIKV in pregnancy</td>
<td>1. Confirmed (n=80) 2. Suspected (n=207)</td>
<td>NR NR 11% 7%</td>
<td></td>
</tr>
<tr>
<td>Brazil&lt;sup&gt;17&lt;/sup&gt;</td>
<td>Symptoms of ZIKV in pregnancy</td>
<td>1. Confirmed MIP (n=57)</td>
<td>28% “Adverse outcomes” 26%</td>
<td></td>
</tr>
<tr>
<td>Barcelona&lt;sup&gt;57&lt;/sup&gt;</td>
<td>ZIKV surveillance travellers</td>
<td>1. Confirmed MIP (n=9) 2. Probable MIP (n=62)</td>
<td>33% “Adverse outcomes” 0%</td>
<td>NR NR</td>
</tr>
</tbody>
</table>

NR: Not Reported; MIP: Maternal Infection in Pregnancy; USZPR United States Zika in Pregnancy Register
References

12 PAHO, WHO. Epidemiological Alert: Zika virus infection. 2015. DOI:10.1111/1469-0691.12707.
13 Gulland A. Zika virus is a global public health emergency, declares WHO. *BMJ* 2016; **352**: i657.


Role of the funding source
Please disclose any funding sources and their role, if any, in the writing of the manuscript or the decision to submit it for publication. Examples of involvement include: data collection, analysis, or interpretation; trial design; patient recruitment; or any aspect pertinent to the study. Please also comment whether you have been paid to write this article by a pharmaceutical company or other agency. If you are the corresponding author, please indicate if you had full access to all the data in the study and had final responsibility for the decision to submit for publication. The information provided here must match the role of the funding source statement in the manuscript.

The funding source had no role in the drafting of this paper or the decision to submit.

Conflicts of interest
Please complete the ICMJE conflict of interest form, which is available at http://www.thelancet.com/forms/icmje-coi. Please ensure that a conflict of interest statement is included at the end of the manuscript, which matches what is declared on the ICMJE conflict of interest form.

Patient consent (if applicable) - completion of this section is mandatory for Clinical Pictures, and Grand Round.
Please sign below to confirm that all necessary consents required by applicable law from any relevant patient, research participant, and/or other individual whose information is included in the article have been obtained in writing. The signed consent form(s) should be retained by the corresponding author and NOT sent to The Lancet Infectious Diseases.

I agree with the plan to submit to The Lancet Infectious Diseases: the contents of the manuscript; to being listed as an author; and to the conflicts of interest statement as summarized. I have had access to all the data in the study (for original research articles) and accept responsibility for its validity.

Title and name: Celia C. CHRISTIE Highest degree: DM, PhD Signature: ________________ Date: ________________

Title and name: 
Highest degree: 
Signature: ________________ Date: 

Title and name: 
Highest degree: 
Signature: ________________ Date: 

Title and name: 
Highest degree: 
Signature: ________________ Date: 

Title and name: 
Highest degree: 
Signature: ________________ Date: 

Title and name: 
Highest degree: 
Signature: ________________ Date: 

Title and name: 
Highest degree: 
Signature: ________________ Date: 

Title and name: 
Highest degree: 
Signature: ________________ Date: 

Title and name: 
Highest degree: 
Signature: ________________ Date: 

Title and name: 
Highest degree: 
Signature: ________________ Date: 

Corresponding author declaration
I __________________________, the corresponding author of this manuscript, certify that the contributors' and conflicts of interest statements included in this paper are correct and have been approved by all co-authors.
Author statements

Please insert the relevant text under the subheadings below. A completed form must be signed by all authors. Please note that we will accept hand-signed and electronic (typed) signatures. Please complete multiple forms if necessary, and upload the signed copy with your submission, scan and email to: IEditorial@lancet.com.

Manuscript title: Researching Zika in pregnancy: lessons for global preparedness

Corresponding author: A E Ades

Article type: Personal view

For research articles only:

Irrevocably authorise and grant my full consent to the corresponding author of the manuscript to: (1) enter into an exclusive publishing agreement with Elsevier on my behalf, in the relevant form set out at www.elsevier.com/copyright, and (2) unless I am a US government employee, to transfer my copyright or grant an exclusive license of rights to Elsevier as part of that publishing agreement, effective on acceptance of the article for publication. If the article is a work made for hire, I am authorized to confirm this on behalf of my employer. I agree that the copyright status selected by the corresponding author for the article shall apply and that this agreement is subject to the governing law of England and Wales.

Does your manuscript have a reference number? No ☐ Yes ☑ If yes, enter number here: 19 - 00512

Does your manuscript have a handling editor? No ☐ Yes ☑ If yes, enter name here: Sally Hargreaves

Authors' contributions

Please insert here the contribution each author made to the manuscript—e.g., literature search, figures, study design, data collection, data analysis, data interpretation, writing etc. If all authors contributed equally, please state this. The information provided here must match the contributors' statement in the manuscript.
THE LANCET
Infectious Diseases

Role of the funding source
Please disclose any funding sources and their role, if any, in the writing of the manuscript or the decision to submit it for publication. Examples of involvement include: data collection, analysis, or interpretation; trial design; patient recruitment; or any aspect pertinent to the study. Please also comment whether you have been paid to write this article by a pharmaceutical company or other agency. If you are the corresponding author, please indicate if you had full access to all the data in the study and had final responsibility for the decision to submit for publication. The information provided here must match the role of the funding source statement in the manuscript.

The funding source had no role in the drafting of this paper or the decision to submit.

Conflicts of interest
Please complete the ICMJE conflict of interest form, which is available at http://www.thelancet.com/for-authors/forms#icmje-coi. Please ensure that a conflict of interest statement is included at the end of the manuscript, which matches what is declared on the ICMJE conflict of interest form.

Patient consent (if applicable) - completion of this section is mandatory for Clinical Pictures, and Grand Round.
Please sign below to confirm that all necessary consents required by applicable law from any relevant patient, research participant, and/or other individual whose information is included in the article have been obtained in writing. The signed consent form(s) should be retained by the corresponding author and NOT sent to The Lancet Infectious Diseases.

I agree with: the plan to submit to The Lancet Infectious Diseases; the contents of the manuscript; to being listed as an author; and to the conflicts of interest statement as summarised. I have had access to all the data in the study (for original research articles) and accept responsibility for its validity.

Title and name: Dr David Brown
Highest degree: PhD
Signature: [Signature]
Date: 21/10/201

Title and name: 
Highest degree: 
Signature: 
Date: 

Title and name: 
Highest degree: 
Signature: 
Date: 

Title and name: 
Highest degree: 
Signature: 
Date: 

Title and name: 
Highest degree: 
Signature: 
Date: 

Title and name: 
Highest degree: 
Signature: 
Date: 

Title and name: 
Highest degree: 
Signature: 
Date: 

Title and name: 
Highest degree: 
Signature: 
Date: 

Title and name: 
Highest degree: 
Signature: 
Date: 

Title and name: 
Highest degree: 
Signature: 
Date: 

Corresponding author declaration
I [Signature], the corresponding author of this manuscript, certify that the contributors' and conflicts of interest statements included in this paper are correct and have been approved by all co-authors.
Author statements

Please insert the relevant text under the subheadings below. A completed form must be signed by all authors. Please note that we will accept hand-signed and electronic (typewritten) signatures. Please complete multiple forms if necessary, and upload the signed copy with your submission, scan and email to: IDeditorial@lancet.com.

Manuscript title: Researching Zika in pregnancy: lessons for global preparedness

Corresponding author: A E Ades

Article type: Personal view

For research articles only:
I irrevocably authorise and grant my full consent to the corresponding author of the manuscript to: (1) enter into an exclusive publishing agreement with Elsevier on my behalf, in the relevant form set out at www.elsevier.com/copyright, and (2) unless I am a US government employee, to transfer my copyright or grant an exclusive license of rights to Elsevier as part of that publishing agreement, effective on acceptance of the article for publication. If the article is a work made for hire, I am authorized to confirm this on behalf of my employer. I agree that the copyright status selected by the corresponding author for the article shall apply and that this agreement is subject to the governing law of England and Wales.

Does your manuscript have a reference number? No ☐ Yes ☑ If yes, enter number here: 19-00512

Does your manuscript have a handling editor? No ☐ Yes ☑ If yes, enter name here: Sally Hargreaves

Authors’ contributions
Please insert here the contribution each author made to the manuscript—eg, literature search, figures, study design, data collection, data analysis, data interpretation, writing etc. If all authors contributed equally, please state this. The information provided here must match the contributors’ statement in the manuscript.

Contributed to writing the manuscript
THE LANCET
Infectious Diseases

Role of the funding source
Please disclose any funding sources and their role, if any, in the writing of the manuscript or the decision to submit it for publication. Examples of involvement include: data collection, analysis, or interpretation; trial design; patient recruitment; or any aspect pertinent to the study. Please also comment whether you have been paid to write this article by a pharmaceutical company or other agency. If you are the corresponding author, please indicate if you had full access to all the data in the study and had final responsibility for the decision to submit for publication. The information provided here must match the role of the funding source statement in the manuscript.

The funding source had no role in the drafting of this paper or the decision to submit.

Conflicts of interest
Please complete the ICMJE conflict of interest form, which is available at http://www.thelancet.com/for-authors/forms#icmje-coi. Please ensure that a conflict of interest statement is included at the end of the manuscript, which matches what is declared on the ICMJE conflict of interest form.

Patient consent (if applicable) - completion of this section is mandatory for Clinical Pictures, and Grand Round.
Please sign below to confirm that all necessary consents required by applicable law from any relevant patient, research participant, and/or other individual whose information is included in the article have been obtained in writing. The signed consent form(s) should be retained by the corresponding author and NOT sent to The Lancet Infectious Diseases.

I agree with: the plan to submit to The Lancet Infectious Diseases; the contents of the manuscript; to being listed as an author; and to the conflicts of interest statement as summarised. I have had access to all the data in the study (for original research articles) and accept responsibility for its validity.

<table>
<thead>
<tr>
<th>Title and name</th>
<th>Highest degree</th>
<th>Signature</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prof Catherine Peckham</td>
<td>MD</td>
<td>[Signature]</td>
<td>04 Oct 2019</td>
</tr>
</tbody>
</table>

Corresponding author declaration
I, the corresponding author of this manuscript, certify that the contributors' and conflicts of interest statements included in this paper are correct and have been approved by all co-authors.
Role of the funding source
Please disclose any funding sources and their role, if any, in the writing of the manuscript or the decision to submit it for publication. Examples of involvement include: data collection, analysis, or interpretation; trial design; patient recruitment; or any aspect pertinent to the study. Please also comment whether you have been paid to write this article by a pharmaceutical company or other agency. If you are the corresponding author, please indicate if you had full access to all the data in the study and had final responsibility for the decision to submit for publication. The information provided here must match the role of the funding source statement in the manuscript.

The funding source had no role in the drafting of this paper or the decision to submit.

Conflicts of interest
Please complete the ICMJE conflict of interest form, which is available at http://www.thelancet.com/forms#icmje-coi. Please ensure that a conflict of interest statement is included at the end of the manuscript, which matches what is declared on the ICMJE conflict of interest form.

Patient consent (if applicable) - completion of this section is mandatory for Clinical Pictures, and Grand Round.
Please sign below to confirm that all necessary consents required by applicable law from any relevant patient, research participant, and/or other individual whose information is included in the article have been obtained in writing. The signed consent form(s) should be retained by the corresponding author and NOT sent to The Lancet Infectious Diseases.

I agree with: the plan to submit to The Lancet Infectious Diseases; the contents of the manuscript; to being listed as an author; and to the conflicts of interest statement as summarised. I have had access to all the data in the study (for original research articles) and accept responsibility for its validity.

Title and name: Prof Catherine Peckham
Highest degree: MD
Signature: ___________________________ Date: 04 Oct 2019

Corresponding author declaration
I, the corresponding author of this manuscript, certify that the contributors' and conflicts of interest statements included in this paper are correct and have been approved by all co-authors.
Role of the funding source
Please disclose any funding sources and their role, if any, in the writing of the manuscript or the decision to submit it for publication.
Examples of involvement include: data collection, analysis, or interpretation; trial design; patient recruitment; or any aspect pertinent to the study. Please also comment whether you have been paid to write this article by a pharmaceutical company or other agency. If you are the corresponding author, please indicate if you had full access to all the data in the study and had final responsibility for the decision to submit for publication. The information provided here must match the role of the funding source statement in the manuscript.

The funding source had no role in the drafting of this paper or the decision to submit.

Conflicts of interest
Please complete the ICMJE conflict of interest form, which is available at http://www.thelancet.com/for-authors/forms#cmje-coi. Please ensure that a conflict of interest statement is included at the end of the manuscript, which matches what is declared on the ICMJE conflict of interest form.

Patient consent (if applicable) - completion of this section is mandatory for Clinical Pictures, and Grand Round.
Please sign below to confirm that all necessary consents required by applicable law from any relevant patient, research participant, and/or other individual whose information is included in the article have been obtained in writing. The signed consent form(s) should be retained by the corresponding author and NOT sent to The Lancet Infectious Diseases.

I agree with: the plan to submit to The Lancet Infectious Diseases; the contents of the manuscript; to being listed as an author; and to the conflicts of interest statement as summarised. I have had access to all the data in the study (for original research articles) and accept responsibility for its validity.

<table>
<thead>
<tr>
<th>Title and name</th>
<th>Highest degree</th>
<th>Signature</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prof Catherine Peckham</td>
<td>MD</td>
<td>signature</td>
<td>04 Oct 2019</td>
</tr>
<tr>
<td>Title and name</td>
<td>Highest degree</td>
<td>Signature</td>
<td>Date</td>
</tr>
<tr>
<td>Title and name</td>
<td>Highest degree</td>
<td>Signature</td>
<td>Date</td>
</tr>
<tr>
<td>Title and name</td>
<td>Highest degree</td>
<td>Signature</td>
<td>Date</td>
</tr>
<tr>
<td>Title and name</td>
<td>Highest degree</td>
<td>Signature</td>
<td>Date</td>
</tr>
<tr>
<td>Title and name</td>
<td>Highest degree</td>
<td>Signature</td>
<td>Date</td>
</tr>
<tr>
<td>Title and name</td>
<td>Highest degree</td>
<td>Signature</td>
<td>Date</td>
</tr>
<tr>
<td>Title and name</td>
<td>Highest degree</td>
<td>Signature</td>
<td>Date</td>
</tr>
<tr>
<td>Title and name</td>
<td>Highest degree</td>
<td>Signature</td>
<td>Date</td>
</tr>
</tbody>
</table>

Corresponding author declaration
I , the corresponding author of this manuscript, certify that the contributors’ and conflicts of interest statements included in this paper are correct and have been approved by all co-authors.
Author statements

Please insert the relevant text under the subheadings below. A completed form must be signed by all authors. Please note that we will accept hand-signed and electronic (typewritten) signatures. Please complete multiple forms if necessary, and upload the signed copy with your submission, scan and email to: IDeditorial@lancet.com.

Manuscript title: Researching Zika in pregnancy: lessons for global preparedness

Corresponding author: A E Ades
Article type: Personal view

For research articles only:
I irrevocably authorise and grant my full consent to the corresponding author of the manuscript to: (1) enter into an exclusive publishing agreement with Elsevier on my behalf, in the relevant form set out at www.elsevier.com/copyright; and (2) unless I am a US government employee, to transfer my copyright or grant an exclusive license of rights to Elsevier as part of that publishing agreement, effective on acceptance of the article for publication. If the article is a work made for hire, I am authorized to confirm this on behalf of my employer. I agree that the copyright status selected by the corresponding author for the article shall apply and that this agreement is subject to the governing law of England and Wales.

Does your manuscript have a reference number? No ☐ Yes ☐ If yes, enter number here: 19 - 00512

Does your manuscript have a handling editor? No ☐ Yes ☐ If yes, enter name here: Sally Hargreaves

Authors' contributions
Please insert here the contribution each author made to the manuscript—eg, literature search, figures, study design, data collection, data analysis, data interpretation, writing etc. If all authors contributed equally, please state this. The information provided here must match the contributors’ statement in the manuscript.

The paper arose from discussions at the November 2017 ZIKAction consortium meeting at University of Florida, Gainesville, FL. AEA drafted the paper with input from all co-authors. The final decision to submit was taken by CT who leads the ZIKAction Vertical Transmission work package. CG is the ZIKAction principal investigator. All co-authors read, contributed to and approved the final version.
THE LANCET
Infectious Diseases

Role of the funding source
Please disclose any funding sources and their role, if any, in the writing of the manuscript or the decision to submit it for publication. Examples of involvement include: data collection, analysis, or interpretation; trial design; patient recruitment; or any aspect pertinent to the study. Please also comment whether you have been paid to write this article by a pharmaceutical company or other agency. If you are the corresponding author, please indicate if you had full access to all the data in the study and had final responsibility for the decision to submit for publication. The information provided here must match the role of the funding source statement in the manuscript.

The funding source had no role in the drafting of this paper or the decision to submit.

Conflicts of interest
Please complete the ICMJE conflict of interest form, which is available at http://www.thelancet.com/for-authors/forms/icmje-coi. Please ensure that a conflict of interest statement is included at the end of the manuscript, which matches what is declared on the ICMJE conflict of interest form.

Patient consent (if applicable) - completion of this section is mandatory for Clinical Pictures, and Grand Round.
Please sign below to confirm that all necessary consents required by applicable law from any relevant patient, research participant, and/or other individual whose information is included in the article have been obtained in writing. The signed consent form(s) should be retained by the corresponding author and NOT sent to The Lancet Infectious Diseases.

I agree with: the plan to submit to The Lancet Infectious Diseases; the contents of the manuscript; to being listed as an author; and to the conflicts of interest statement as summarised. I have had access to all the data in the study (for original research articles) and accept responsibility for its validity.

Title and name: Antoni Soriano-Arandes
Highest degree: PhD
Signature: ...
Date: 30/07/2019

Title and name:
Highest degree:
Signature: ...
Date:

Title and name:
Highest degree:
Signature: ...
Date:

Title and name:
Highest degree:
Signature: ...
Date:

Title and name:
Highest degree:
Signature: ...
Date:

Title and name:
Highest degree:
Signature: ...
Date:

Title and name:
Highest degree:
Signature: ...
Date:

Title and name:
Highest degree:
Signature: ...
Date:

Title and name:
Highest degree:
Signature: ...
Date:

Title and name:
Highest degree:
Signature: ...
Date:

Title and name:
Highest degree:
Signature: ...
Date:

Corresponding author declaration
I [Signature], the corresponding author of this manuscript, certify that the contributors’ and conflicts of interest statements included in this paper are correct and have been approved by all co-authors.
Author statements

Please insert the relevant text under the subheadings below. A completed form must be signed by all authors. Please note that we will accept hand-signed and electronic (typewritten) signatures. Please complete multiple forms if necessary, and upload the signed copy with your submission, scan and email to: IDeditorial@lancet.com.

Manuscript title: Researching Zika in pregnancy: lessons for global preparedness

Corresponding author: A E Ades

Article type: Personal view

For research articles only:
I irrevocably authorise and grant my full consent to the corresponding author of the manuscript to: (1) enter into an exclusive publishing agreement with Elsevier on my behalf, in the relevant form set out at www.elsevier.com/copyright; and (2) unless I am a US government employee, to transfer my copyright or grant an exclusive license of rights to Elsevier as part of that publishing agreement, effective on acceptance of the article for publication. If the article is a work made for hire, I am authorized to confirm this on behalf of my employer. I agree that the copyright status selected by the corresponding author for the article shall apply and that this agreement is subject to the governing law of England and Wales.

Does your manuscript have a reference number? No [ ] Yes [x] If yes, enter number here: 19 - 00512

Does your manuscript have a handling editor? No [ ] Yes [x] If yes, enter name here: Sally Hargreaves

Authors’ contributions

Please insert here the contribution each author made to the manuscript—eg, literature search, figures, study design, data collection, data analysis, data interpretation, writing etc. If all authors contributed equally, please state this. The information provided here must match the contributors’ statement in the manuscript.
Role of the funding source
Please disclose any funding sources and their role, if any, in the writing of the manuscript or the decision to submit it for publication. Examples of involvement include: data collection, analysis, or interpretation; trial design; patient recruitment; or any aspect pertinent to the study. Please also comment whether you have been paid to write this article by a pharmaceutical company or other agency. If you are the corresponding author, please indicate if you had full access to all the data in the study and had final responsibility for the decision to submit for publication. The information provided here must match the role of the funding source statement in the manuscript.

The funding source had no role in the drafting of this paper or the decision to submit

Conflicts of interest
Please complete the ICMJE conflict of interest form, which is available at http://www.thelancet.com/for-authors/forms#icmje-coi. Please ensure that a conflict of interest statement is included at the end of the manuscript, which matches what is declared on the ICMJE conflict of interest form.

Patient consent (if applicable) - completion of this section is mandatory for Clinical Pictures, and Grand Round.
Please sign below to confirm that all necessary consents required by applicable law from any relevant patient, research participant, and/or other individual whose information is included in the article have been obtained in writing. The signed consent form(s) should be retained by the corresponding author and NOT sent to The Lancet Infectious Diseases.

I agree with: the plan to submit to The Lancet Infectious Diseases; the contents of the manuscript; to being listed as an author; and to the conflicts of interest statement as summarised. I have had access to all the data in the study (for original research articles) and accept responsibility for its validity.

Title and name: Carlo Giaquinto
Highest degree: Prof
Signature: .................................................. Date:

Title and name:
Highest degree:
Signature: .................................................. Date:

Title and name:
Highest degree:
Signature: .................................................. Date:

Title and name:
Highest degree:
Signature: .................................................. Date:

Title and name:
Highest degree:
Signature: .................................................. Date:

Title and name:
Highest degree:
Signature: .................................................. Date:

Title and name:
Highest degree:
Signature: .................................................. Date:

Title and name:
Highest degree:
Signature: .................................................. Date:

Title and name:
Highest degree:
Signature: .................................................. Date:

Title and name:
Highest degree:
Signature: .................................................. Date:

Title and name:
Highest degree:
Signature: .................................................. Date:

Title and name:
Highest degree:
Signature: .................................................. Date:

Corresponding author declaration
I [Signature], the corresponding author of this manuscript, certify that the contributors’ and conflicts of interest statements included in this paper are correct and have been approved by all co-authors.
Role of the funding source
Please disclose any funding sources and their role, if any, in the writing of the manuscript or the decision to submit it for publication. Examples of involvement include: data collection, analysis, or interpretation; trial design; patient recruitment; or any aspect pertinent to the study. Please also comment whether you have been paid to write this article by a pharmaceutical company or other agency. If you are the corresponding author, please indicate if you had full access to all the data in the study and had final responsibility for the decision to submit for publication. The information provided here must match the role of the funding source statement in the manuscript.

The funding source had no role in the drafting of this paper or the decision to submit.

Conflicts of interest
Please complete the ICMJE conflict of interest form, which is available at http://www.thelancet.com/for-authors/forms#icmje-coi. Please ensure that a conflict of interest statement is included at the end of the manuscript, which matches what is declared on the ICMJE conflict of interest form.

Patient consent (if applicable) - completion of this section is mandatory for Clinical Pictures, and Grand Round.
Please sign below to confirm that all necessary consents required by applicable law from any relevant patient, research participant, and/or other individual whose information is included in the article have been obtained in writing. The signed consent form(s) should be retained by the corresponding author and NOT sent to The Lancet Infectious Diseases.

I agree with: the plan to submit to The Lancet Infectious Diseases; the contents of the manuscript; to being listed as an author; and to the conflicts of interest statement as summarised. I have had access to all the data in the study (for original research articles) and accept responsibility for its validity.

Title and name: Daniel Lang
Highest degree: Dr.
Signature: .......................... Date: 08102019

Corresponding author declaration
I ______ [Signature] ______, the corresponding author of this manuscript, certify that the contributors' and conflicts of interest statements included in this paper are correct and have been approved by all co-authors.
Author statements

Please insert the relevant text under the subheadings below. A completed form must be signed by all authors. Please note that we will accept hand-signed and electronic (typewritten) signatures. Please complete multiple forms if necessary, and upload the signed copy with your submission, scan and email to: ldeditorial@lancet.com.

Manuscript title: Researching Zika in pregnancy: lessons for global preparedness

Corresponding author: A E Ades
Article type: Personal view

For research articles only:
I irrevocably authorise and grant my full consent to the corresponding author of the manuscript to: (1) enter into an exclusive publishing agreement with Elsevier on my behalf, in the relevant form set out at www.elsevier.com/copyright; and (2) unless I am a US government employee, to transfer my copyright or grant an exclusive license of rights to Elsevier as part of that publishing agreement, effective on acceptance of the article for publication. If the article is a work made for hire, I am authorized to confirm this on behalf of my employer. I agree that the copyright status selected by the corresponding author for the article shall apply and that this agreement is subject to the governing law of England and Wales.

Does your manuscript have a reference number? No ☐ Yes ☑ If yes, enter number here: 19-00512

Does your manuscript have a handling editor? No ☐ Yes ☑ If yes, enter name here: Sally Hargreaves

Authors' contributions
Please insert here the contribution each author made to the manuscript—eg, literature search, figures, study design, data collection, data analysis, data interpretation, writing etc. If all authors contributed equally, please state this. The information provided here must match the contributors' statement in the manuscript.

The paper arose from discussions at the November 2017 ZIKAction consortium meeting at University of Florida, Gainesville, FL. AEA drafted the paper with input from all co-authors. The final decision to submit was taken by CT who leads the ZIKAction Vertical Transmission work package. CG is the ZIKAction principal investigator. All co-authors read, contributed to and approved the final version.
Author statements

Please insert the relevant text under the subheadings below. A completed form must be signed by all authors. Please note that we will accept hand-signed and electronic (typewritten) signatures. Please complete multiple forms if necessary, and upload the signed copy with your submission, scan and email to: IDeditorial@lancet.com.

**Manuscript title:** Researching Zika in pregnancy: lessons for global preparedness

**Corresponding author:** A E Ades

**Article type:** Personal view

*For research articles only:*
I irrevocably authorise and grant my full consent to the corresponding author of the manuscript to: (1) enter into an exclusive publishing agreement with Elsevier on my behalf, in the relevant form set out at [www.elsevier.com/copyright](http://www.elsevier.com/copyright); and (2) unless I am a US government employee, to transfer my copyright or grant an exclusive license of rights to Elsevier as part of that publishing agreement, effective on acceptance of the article for publication. If the article is a work made for hire, I am authorized to confirm this on behalf of my employer. I agree that the copyright status selected by the corresponding author for the article shall apply and that this agreement is subject to the governing law of England and Wales.

Does your manuscript have a reference number? No [ ] Yes [ ] If yes, enter number here: 19 - 00512

Does your manuscript have a handling editor? No [ ] Yes [ ] If yes, enter name here: Sally Hargreaves

**Authors’ contributions**
Please insert here the contribution each author made to the manuscript—eg, literature search, figures, study design, data collection, data analysis, data interpretation, writing etc. If all authors contributed equally, please state this. The information provided here must match the contributors’ statement in the manuscript.
Role of the funding source
Please disclose any funding sources and their role, if any, in the writing of the manuscript or the decision to submit it for publication. Examples of involvement include: data collection, analysis, or interpretation; trial design; patient recruitment; or any aspect pertinent to the study. Please also comment whether you have been paid to write this article by a pharmaceutical company or other agency. If you are the corresponding author, please indicate if you had full access to all the data in the study and had final responsibility for the decision to submit for publication. The information provided here must match the role of the funding source statement in the manuscript.

The funding source had no role in the drafting of this paper or the decision to submit

Conflicts of interest
Please complete the ICMJE conflict of interest form, which is available at http://www.thelancet.com/for-authors/forms#icmje-coi. Please ensure that a conflict of interest statement is included at the end of the manuscript, which matches what is declared on the ICMJE conflict of interest form.

Patient consent (if applicable) - completion of this section is mandatory for Clinical Pictures, and Grand Round.
Please sign below to confirm that all necessary consents required by applicable law from any relevant patient, research participant, and/or other individual whose information is included in the article have been obtained in writing. The signed consent form(s) should be retained by the corresponding author and NOT sent to The Lancet Infectious Diseases.

I agree with: the plan to submit to The Lancet Infectious Diseases; the contents of the manuscript; to being listed as an author; and to the conflicts of interest statement as summarised. I have had access to all the data in the study (for original research articles) and accept responsibility for its validity.

Title and name: Professor J. Glenn Morris
Highest degree: MD
Signature: J. Glenn Morris, Jr.
Date: 2019.09.30

Corresponding author declaration
I [Signature], the corresponding author of this manuscript, certify that the contributors’ and conflicts of interest statements included in this paper are correct and have been approved by all co-authors.
Author statements

Please insert the relevant text under the subheadings below. A completed form must be signed by all authors. Please note that we will accept hand-signed and electronic (typewritten) signatures. Please complete multiple forms if necessary, and upload the signed copy with your submission, scan and email to: IDeditorial@lancet.com.

Manuscript title: Researching Zika in pregnancy: lessons for global preparedness

Corresponding author: A E Ades

Article type: Personal view

For research articles only:
I irrevocably authorise and grant my full consent to the corresponding author of the manuscript to: (1) enter into an exclusive publishing agreement with Elsevier on my behalf, in the relevant form set out at www.elsevier.com/copyright; and (2) unless I am a US government employee, to transfer my copyright or grant an exclusive license of rights to Elsevier as part of that publishing agreement, effective on acceptance of the article for publication. If the article is a work made for hire, I am authorized to confirm this on behalf of my employer. I agree that the copyright status selected by the corresponding author for the article shall apply and that this agreement is subject to the governing law of England and Wales.

Does your manuscript have a reference number? No ❑ Yes ☑ If yes, enter number here: 19 - 00512

Does your manuscript have a handling editor? No ❑ Yes ☑ If yes, enter name here: Sally Hargreaves

Authors’ contributions
Please insert here the contribution each author made to the manuscript—eg, literature search, figures, study design, data collection, data analysis, data interpretation, writing etc. If all authors contributed equally, please state this. The information provided here must match the contributors’ statement in the manuscript.

CT contributed to literature search and drafting of the manuscript.
Role of the funding source
Please disclose any funding sources and their role, if any, in the writing of the manuscript or the decision to submit it for publication. Examples of involvement include: data collection, analysis, or interpretation; trial design; patient recruitment; or any aspect pertinent to the study. Please also comment whether you have been paid to write this article by a pharmaceutical company or other agency. If you are the corresponding author, please indicate if you had full access to all the data in the study and had final responsibility for the decision to submit for publication. The information provided here must match the role of the funding source statement in the manuscript.

The funding source had no role in the drafting of this paper or the decision to submit

Conflicts of interest
Please complete the ICMJE conflict of interest form, which is available at http://www.thelancet.com/for-authors/forms#icmje-coi. Please ensure that a conflict of interest statement is included at the end of the manuscript, which matches what is declared on the ICMJE conflict of interest form.

Patient consent (if applicable) - completion of this section is mandatory for Clinical Pictures, and Grand Round.
Please sign below to confirm that all necessary consents required by applicable law from any relevant patient, research participant, and/or other individual whose information is included in the article have been obtained in writing. The signed consent form(s) should be retained by the corresponding author and NOT sent to The Lancet Infectious Diseases.

I agree with: the plan to submit to The Lancet Infectious Diseases; the contents of the manuscript; to being listed as an author; and to the conflicts of interest statement as summarised. I have had access to all the data in the study (for original research articles) and accept responsibility for its validity.

Title and name: Prof Claire Thorne
Highest degree: PhD
Signature: .................................. Date: 11/10/19

Corresponding author declaration

I __________________________, the corresponding author of this manuscript, certify that the contributors’ and conflicts of interest statements included in this paper are correct and have been approved by all co-authors.
Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit http://www.adobe.com/go/acrreader.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.
ICMJE Form for Disclosure of Potential Conflicts of Interest

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. **Identifying information.**

2. **The work under consideration for publication.**

   This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. **Relevant financial activities outside the submitted work.**

   This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

   Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work’s sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

   For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. **Intellectual Property.**

   This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

5. **Relationships not covered above.**

   Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

**Definitions.**

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent
ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 1. Identifying Information

1. Given Name (First Name) Daniel
2. Surname (Last Name) Lang
3. Date 08-October-2019
4. Are you the corresponding author? ☑ No
5. Manuscript Title
Researching Zika in pregnancy: lessons for global awareness
6. Manuscript Identifying Number (if you know it)
19 - 00512

Section 2. The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?
Are there any relevant conflicts of interest? ☑ No

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication.
Are there any relevant conflicts of interest? ☑ No

Section 4. Intellectual Property -- Patents & Copyrights

Do you have any patents, whether planned, pending or issued, broadly relevant to the work? ☑ No

Lang
ICMJE Form for Disclosure of Potential Conflicts of Interest

Section 5. Relationships not covered above

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☑ Yes, the following relationships/conditions/circumstances are present (explain below):
☐ No other relationships/conditions/circumstances that present a potential conflict of interest

All authors have received funding through the ZIKAction consortium

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Section 6. Disclosure Statement

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Lang reports and All authors have received funding through the ZIKAction consortium.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.
Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit http://www.adobe.com/go/acrreader.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.
Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit http://www.adobe.com/go/acrreader.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.
Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit http://www.adobe.com/go/acrreader.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.
Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit http://www.adobe.com/go/acrreader.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.
Please wait...

If this message is not eventually replaced by the proper contents of the document, your PDF viewer may not be able to display this type of document.

You can upgrade to the latest version of Adobe Reader for Windows®, Mac, or Linux® by visiting http://www.adobe.com/go/reader_download.

For more assistance with Adobe Reader visit http://www.adobe.com/go/acrreader.

Windows is either a registered trademark or a trademark of Microsoft Corporation in the United States and/or other countries. Mac is a trademark of Apple Inc., registered in the United States and other countries. Linux is the registered trademark of Linus Torvalds in the U.S. and other countries.
To Whom It May Concern,

This is to confirm that I consent to my name appearing in the acknowledgments section of the “Researching Zika in pregnancy: lessons for global preparedness” research article, submitted to Lancet ID by AE Ades.

Yours Faithfully,
Thomas Byrne

28.11.2019